Biontech and medigene announce global collaboration to advance t cell receptor immunotherapies against cancer

Mainz/martinsried/munich, germany, february 21, 2022 – biontech se (nasdaq: bntx, “biontech”) and medigene ag (fse: mdg1, prime standard, “medigene”), a clinical-stage immuno-oncology company focusing on the development of t cell immunotherapies, today announced that they have entered a multi-target research collaboration to develop t cell receptor (tcr) based immunotherapies against cancer. the initial term of the collaboration is three years.
BNTX Ratings Summary
BNTX Quant Ranking